Gold(I)phosphines, nucleoside analogues, and azole derivatives have been identified as promising anticancer compounds. The clinical use of these individual compounds is, however, limited due to non-selectivity associated with adverse effects and developed resistance. This study investigated seven novel gold compounds that contain either a nucleoside analogue or an azole, bound via a gold nitrogen bond, which have been designed and synthesized by Dr. Horvath under the supervision of Prof. Raubenheimer from the University of Stellenbosch. The novel compounds are divided into purinecontaining/ nucleoside analogue compounds (UH 86.2, UH 75.1, UH 58.1, UH 145.1) and azole-containing compounds (UH 107.1, UH 126.1, UH 127.1). The anticancer effects of these novel compounds were compared with that of previously described anticancer compounds [Au(dppe)2]Cl and cisplatin. The octanol/water partition coefficients (PC) of the compounds were measured in order to determine whether a correlation between the lipophilicity of the structures and the cytotoxic potency and selectivity exists. This might provide further insight for structural alterations of the compounds in order to improve their anticancer activity. The results from octanol/water PC determinations, revealed that the purine-containing compounds (UH 86.2, UH 75.1, UH 58.1, and UH 145.1), as well as the azole-containing compound, UH 127.1, exhibited hydrophilic properties, while the azole-containing compounds, UH 107.1 and UH 126.1 are lipophilic. In contrast to results by Berners-Price et al. (1999), that reported a direct proportionality between lipophilicity and cytotoxicity, for the current study, involving HeLa cells, CoLo cells, normal resting and PHA stimulated lymphocytes, no correlation was observed. For the Jurkat cell line, however, an increase in lipophilicity for the series of compounds studied was accompanied by an increase in cytotoxicity. The reason for the exception is not yet fully understood. The in vitro tumour specificity of each compound was established with cytotoxicity assays on various cancer cell lines and normal cell cultures. The cancer cell lines included human cervical cancer (HeLa) cells, human colon cancer (CoLo) cells, and human lymphocytic leukaemia (Jurkat) cells. The normal cell cultures included human resting lymphocytes and human phytohemaglutin (PHA) stimulated lymphocytes. From this data, the four most promising novel compounds were identified. Additional tests were performed by adding these four compounds to cancer cells including human breast cancer (MCF-7) cells, and cisplatin sensitive and resistant human ovarian cancer (A2780 and A2780cis) cells as well as normal chicken embryo fibroblasts. The tumour specificity of each compound was determined from the results obtained via the cytotoxicity assays. The compound is more selective the higher the tumour specificity. Cisplatin exhibited the highest tumour specificity, and [Au(dppe)2]Cl, the lowest. The two most promising novelcompounds were identified as UH 126.1 and UH 127.1, which was evidenced by their high tumour specificities. Further experiments were conducted with these two azolecontaining compounds by using Jurkat cells. The possible mechanism by which the novel compounds induce cytotoxicity was investigated with flow cytometric analysis. The effects of the compounds on the cell death pathway, the mitochondrial membrane potential and the cell cycle were determined. These results indicated that the novel compounds, UH 126.1 and UH 127.1 initiate the apoptotic cell death pathway rather than the necrotic cell death pathway. According to results, UH 126.1 and UH 127.1 influenced the status of the mitochondrial membrane potential (MMP) non-selectively and only at high concentrations. Although involvement of mitochondria in the mechanism of action cannot be excluded, results indicated that it is most likely not the primary target. After investigating the effects of the two novel azole-containing compounds on the cell cycle in Jurkat cells, it was detected that these compounds induce cell accumulation in the G1 phase of the cell cycle. It was concluded that UH 126.1 and UH 127.1 might interfere with the cell cycle indirectly, possibly by inhibition of cyclin-dependent kinases and/or other enzymes necessary for DNA replication. In an acute in vivo toxicity test during this study, results revealed drug induced adverse effects (such as significant weight loss, piloerection and diarrhoea), in the mice that received 3 and 6ìmol/kg of both UH 126.1 and UH 127.1. Evidence also revealed signs of nephrotoxicity and epatotoxicity. Due to minimal adverse effects observed in the groups that received UH 126.1 and UH 127.1 at the concentration of 1,5ìmol/kg, this is the suggested maximum tolerated dose (MTD) for these compounds. Further dose-range studies with UH 126.1 and UH 127.1 are, however, needed in order to evaluate clinicalefficacy. Copyright / Dissertation (MSc)--University of Pretoria, 2009. / Pharmacology / unrestricted

M.Sc. / This study comprised the synthesis and characterization of new carbonyl carbene complexes of chromium, molybdenum and tungsten, prepared from thiazole precursors. In addition, the preparation and characterization of coordination compounds of chromium, tungsten and iron with new thiazole dithiocarboxylester ligands are reported.

The bis(2-pyridylthio)methyl ligand, [Bptm], offers a synthetically convenient alternative to a variety of multidentate ligands, including most notably [Tptm] (tris(2-pyridylthio)methyl) and [BptmSTol] (bis(2-pyridylthio)(p-tolylthio)methyl), and, in contrast with [Tptm], necessarily coordinates to metal centers in a κ³ fashion. As such, numerous [Bptm] complexes of zinc have been synthesized and structurally characterized. In Chapter 1, we describe the reaction of the protonated ligand [Bptm]H with the homoleptic zinc compounds Me₂Zn and Zn[N(SiMe₃)₂]₂ to afford, respectively, [Bptm]ZnMe and [Bptm]ZnN(SiMe₃)₂; the latter has been used as a starting point for a wide range of reactivity.Most notably, the terminal zinc hydride, [Bptm]ZnH, can be accessed via either (i) metathesis of the zinc siloxide, [Bptm]ZnOSiPh₃, with either PhSiH₃ or HBpin, or (ii) direct metathesis of the zinc amide [Bptm]ZnN(SiMe₃)₂ with HBpin; the latter reactivity is not precedented and offers a novel approach for the synthesis of molecular zinc hydrides. Both [Bptm]ZnN(SiMe₃)2 and [Bptm]ZnH provide access to a variety of monomeric derivatives, including the zinc halides [Bptm]ZnX (X = Cl, Br, I) and the zinc isocyanate [Bptm]ZnNCO; the latter can be accessed directly via (i) metathesis of [Bptm]ZnH with Me₃SiNCO or (ii) a multistep reaction of [Bptm]ZnN(SiMe₃)₂ with CO₂. [Bptm]ZnH also undergoes insertion of CO₂ into its Zn—H bond to afford the zinc formate, [Bptm]ZnO₂CH, in which the formate moiety exhibits a monodentate binding mode in the solid state. This reactivity enables it to serve as a catalyst for the hydrofunctionalization of CO₂; specifically, [Bptm]ZnH catalyzes the hydrosilylation of CO₂ by (RO)₃SiH (R = Me, Et) at elevated temperatures to afford the respective silyl formates (RO)3SiO₂CH, as well as the hydroboration of CO₂ by HBpin at room temperature to afford the boryl formate HCO₂Bpin. In the absence of CO₂, [Bptm]ZnH also catalyzes the reduction of HCO₂Bpin to the methanol level, MeOBpin. Similarly, [Bptm]ZnH serves as an effective catalyst for the hydrosilylation and hydroboration of a variety of ketones and aldehydes. In all cases, hydroboration is more facile than the corresponding hydrosilylation. The [Bptm]Zn system has been investigated computationally, and the kinetics of insertion of CO₂ into the Zn—H bond of [Bptm]ZnH as well as the thermodynamics of the catalytic cycle have been examined. Further mechanistic studies examine two noteworthy spectroscopic features of the system, namely rapid exchange (i) between the zinc and boryl formates [Bptm]ZnO₂CH and HCO₂Bpin, as well as (ii) between [Bptm]ZnH and [Bptm]ZnO₂CH. Both of these exchange processes have been investigated with variable-temperature NMR spectroscopy; in particular, the former exchange resolves at low temperatures and can be confirmed by exchange spectroscopy. In addition to the aforementioned monomeric zinc halides [Bptm]ZnX (X = Cl, Br, I), the dimeric bridging zinc fluoride {[Bptm]Zn(μ-F)}₂ has been synthesized via reaction of Me3SnF with either [Bptm]ZnN(SiMe₃)₂ or [Bptm]ZnH, as outlined in Chapter 2. The dimeric nature of the fluoride in contrast with the other monomeric halides can be attributed to the significant polarity of the Zn—F bond. {[Bptm]Zn(μ-F)}2 also reacts with Me₃SiCF₃ to afford an unusual instance of a structurally characterized zinc trifluoromethyl complex, [Bptm]ZnCF₃. Chapter 3 discusses cadmium analogues to the [Bptm]Zn system, which provide a comparison and a contrast both with their zinc counterparts as well as with previously reported [Tptm]Cd complexes. While the cadmium amide [Bptm]CdN(SiMe₃)2 may be synthesized in a manner corresponding to that for its zinc analogue, the siloxides {[Bptm]Zn(μ-OSiR₃)}₂ (R = Me, Ph) form dimers that are distinct from the monomeric [Bptm]ZnOSiPh₃ and [Tptm]CdOSiPh₃, although similar to {[Tptm]Cd(μ-OSiMe₃)}₂. The distinctions between the [Bptm]Zn and [Bptm]Cd siloxides have been investigated computationally, indicating that the cadmium species show a thermodynamic preference for dimer formation, which can be attributed to the larger atomic radius of cadmium relative to zinc. Attempts to synthesize a cadmium hydride are interrupted by a Schlenk-type equilibrium giving way to the bis(ligand) complex [Bptm]2Cd and CdH₂, which in turn decomposes to Cd and H2. However, spectroscopic studies indicate that under CO₂, [Bptm]CdN(SiMe₃)₂ and HBpin react to trap a cadmium hydride species as the bridging formate derivative, [Bptm]Cd(μ-O₂CH)₂Bpin. The interaction of nitrogen-rich ligands with main group metals is further probed in Chapter 4, which describes the investigation of the coordination of 2,2’:6,2”-terpyridine (terpy) to magnesium compounds. Most prominently, unsubsituted terpy forms an adduct, terpyMg[N(SiMe₃)₂]₂, with the monomeric form of the magnesium amide {Mg[N(SiMe₃)₂]₂}₂. The adduct reacts with halide donors to form a series of mixed amide-halide complexes, terpyMg[N(SiMe₃)]X (X = Cl, Br, I), as well as a mixed amide-azide complex, terpyMg[N(SiMe₃)₂]N₃. These complexes represent the first instances of neutral monomeric terpyMg compounds that feature unsubstituted terpyridine. Structural comparisons of these complexes with one another as well as with comparable compounds are undertaken. Complexes of terpy with cadmium and zinc analogues, terpyCd[N(SiMe₃)₂]₂ and terpyZn [N(SiMe₃)₂]₂, are explored further, and DFT calculations are used to explore the strength of the interactions between the ligand and the metals in each case. Finally, in Chapter 5, attention is given to the recently reported zinc bromide complex featuring a zwitterionic carboxylate ligand, (Cbp)2ZnBr₂. The structure reported for this complex features several anomalous features, including abnormally long Zn—Br and Zn—O bonds, unusually small atomic displacement parameters for Zn, and a high R-value. This information led us to synthesize and investigate the cadmium counterpart, (Cbp)₂CdBr₂; we find that the cadmium complex possesses nearly identical structural parameters to the reported zinc complex, and when the cadmium is refined as zinc, the displacement parameter problems are reproduced. Therefore, we conclude that the reported structure is in fact that of (Cbp)₂CdBr₂, and report a revised structure for (Cbp)₂ZnBr₂.

No description available.

Call number: LD2668 .T4 1964 D69 / Master of Science

Call number: LD2668 .T4 1978 J34 / Master of Science

No description available.

published_or_final_version / Chemistry / Doctoral / Doctor of Philosophy

published_or_final_version / Chemistry / Doctoral / Doctor of Philosophy

published_or_final_version / Chemistry / Doctoral / Doctor of Philosophy